Mobile Health Topic of the Week

Apple Heart Study versus Huawei Heart Study

Atrial fibrillation is the most common arrhythmia, affecting 2-3% of the population. Patients suffer from palpitations and/or shortness of breath. They are also at increased risk of stroke, heart failure and dementia. Early diagnosis allows for timely initiation of treatment, which can prove life-saving. Apple and Huawei believe that the photoplethysmography sensors on their wearables can warn their users about atrial fibrillation episodes.

The Apple Heart Study and the Huawei Heart Study investigated this hypothesis.

Take-home messages

  • Both devices appear capable of detecting AF episodes.
  • We don’t know how many AF episodes went undetected.
  • We await to see how Apple’s one-lead ECG performs in upcoming clinical trials.

These may also interest you

Heartbeat Health teams up with the ACC

AIs that stare at ECGs: Taiwanese AI outperforms doctors in 13 ECG patterns

The American College of Cardiology will use BioIntellisense tech in its ΑCC.21 congress to protect participants from COVID-19